Pharma News
16 Nov 2025 to 22 Nov 2025
Nov 22, 2025
Government intends to take action against drug advertisements, according to DrugsControl Media Services.
The Centre is set to implement stricter regulations on drug advertisements to combat the rising online promotion of potent antibiotics, psychotropic drugs, hormonal treatments, and counterfeit imported medicines. This initiative aims to enhance consumer safety and ensure responsible marketing practices in the pharmaceutical industry.
Nov 22, 2025
BioNxt Solutions awarded Eurasian Patent for its sublingual cladribine technology.
BioNxt Solutions Inc. has received a patent from the Eurasian Patent Organization for its sublingual delivery system of anticancer drugs, including BNT23001, a formulation of cladribine for multiple sclerosis. The patent, valid until June 14, 2043, covers eight EAPO member states. CEO Hugh Rogers highlighted its significance for commercialization and ongoing studies, with further patent efforts underway globally.
Nov 22, 2025
FDA's strategy to enhance biosimilar medications may face delays at the patent office - Press Telegram
The FDA plans to streamline the approval process for biosimilars, potentially reducing costs by up to 90% for drugs like Humira and Keytruda. However, the U.S. Patent Office's new rules complicate market entry for these cheaper alternatives, as patent challenges become more difficult. Industry officials express concern over the impact on drug affordability and access.
Nov 22, 2025
Novo Nordisk Confronts Increasing Legal and Market Challenges - Ad-hoc-news.de
Novo Nordisk faces significant challenges following a Danish ruling that approved damages for patients who suffered blindness linked to its GLP-1 drugs, Wegovy and Ozempic. This decision intensifies investor anxiety amid stock declines and price competition, particularly against Eli Lilly. The company is also implementing cost-cutting measures, including layoffs, as it navigates a complex legal landscape and eroding investor confidence.
Nov 22, 2025
Recent findings indicate that tirzepatide and semaglutide provide significant cardiovascular protection. | ScienceDaily
A study from Mass General Brigham published in Nature Medicine reveals that both tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) significantly reduce the risk of heart attack, stroke, and death in type 2 diabetes patients. The research indicates minimal differences in cardiovascular protection between the two drugs, suggesting both are effective for clinical use.
Nov 22, 2025
Eli Lilly emerges as the first healthcare company to reach a $1 trillion valuation, capturing Wall Street's attention.
Eli Lilly has become the first healthcare company to achieve a $1 trillion market valuation, driven by its blockbuster drugs Mounjaro and Zepbound. The company captured nearly 60% of US GLP-1 prescriptions, significantly outpacing competitor Novo Nordisk. Analysts predict substantial growth in the obesity drug market, with Lilly's portfolio potentially reaching $101 billion in peak revenue.
Nov 22, 2025
QURX Pharmaceuticals Facility in Sansarpur Terrace Shut Down Due to Claims of Counterfeit Medications
Authorities in Himachal Pradesh have sealed the QURX Pharmaceuticals factory in Sansarpur Terrace due to allegations of producing counterfeit drugs. This action, taken by the Kangra district Dehra police and the state drug department, marks a significant step in combating the counterfeit drug trade in the region.
Nov 22, 2025
Calls for Enhanced Regulation and Clarity in the Worldwide Generic Medication Supply Chain
U.S. Senator Rick Scott is advocating for reforms to enhance oversight and transparency in the global supply chain for generic drugs. This push follows alarming reports of contamination, prompting calls for federal regulators to take action.
Nov 21, 2025
Pharmacies Across the Country Now Required to Use QR Codes for Reporting Adverse Drug Reactions
The Drugs Controller General of India (DCGI) has mandated that all retail and wholesale pharmacies must display QR codes for reporting adverse drug reactions. This initiative aims to strengthen pharmacovigilance and enable citizens to monitor drug safety more effectively.
Nov 21, 2025
Eli Lilly Achieves Milestone as the First Healthcare Firm to Attain a $1 Trillion Market Capitalization
Eli Lilly achieved a historic milestone on November 21, 2025, with its stock reaching a $1 trillion market capitalization, driven by strong sales of its diabetes drug Mounjaro and weight loss injection Zepbound. Mounjaro generated $6.52 billion in Q3 revenue, while Zepbound brought in $3.59 billion. Analysts anticipate further growth with upcoming oral versions of these drugs.
Nov 21, 2025
NVS Increases Sales Forecasts Driven by Major Medications and Partnerships - Yahoo Finance
Novartis (NVS) projects a 5-6% sales growth CAGR for 2025-2030, raising its 2024-2029 guidance to 6%. Key products like Kisqali and Scemblix drive momentum, despite competition for Entresto. Kisqali's peak sales forecast increased to over $10 billion, while Scemblix is expected to reach $4 billion. Novartis also received FDA approval for Rhapsido, a treatment for chronic spontaneous urticaria.
Nov 21, 2025
Eli Lilly achieves a $1 trillion valuation, becoming the first pharmaceutical company to do so, driven by the surge in weight-loss treatments.
Eli Lilly has made history by becoming the first pharmaceutical company to achieve a $1 trillion market valuation, driven by the success of its incretin-based drugs, Mounjaro and Zepbound. Mounjaro generated $6.52 billion in revenue, while Zepbound reached $3.59 billion. Lilly's market share in the incretin drug sector is now 57.9%, outpacing competitors like Novo Nordisk.
Nov 21, 2025
Novo and Lilly partner with Waltz Health to offer weight-loss medications directly to employers.
Waltz Health has launched a program to provide weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, starting January 1. This initiative aims to streamline access through existing healthcare providers or telehealth, enhancing pricing transparency and adherence monitoring. Novo and Lilly are focused on combating unapproved versions of their GLP-1 hormone-based treatments in the growing obesity market.
Nov 21, 2025
What Mechanisms Do Weight-Loss Drugs Use to Curb Appetite in the Brain? | Health and Me
Weight-loss drugs like tirzepatide are shown to reduce food cravings by quieting 'food noise' in the brain, helping to control appetite and promote healthier eating habits. These medications work effectively under expert guidance to support weight management.
Nov 21, 2025
Crucial Alzheimer's research by Novo Nordisk may provide insights into the advantages of GLP-1.
Novo Nordisk's upcoming trials for its diabetes drug Rybelsus, which contains semaglutide, aim to determine if it can slow cognitive decline in Alzheimer's patients. Success could offer a safer alternative to current amyloid-targeting treatments and potentially boost Novo's shares. Results are expected on December 3 at the Clinical Trials on Alzheimer’s Disease meeting.
Nov 21, 2025
Eli Lilly Achieves $1 Trillion Valuation, Driven by Strong Demand for Its Weight Loss Medications
Eli Lilly has become the first publicly traded health care company to reach a market value of $1 trillion, driven by the success of its weight loss drugs, particularly GLP-1s like Zepbound and Mounjaro. This milestone highlights the growing potential of the weight loss medicine market, surpassing competitors like Johnson & Johnson, valued at around $500 billion.
Nov 21, 2025
Implementing Therapy Using Psychedelic Substances Necessitates Recognizing Historical Context... - JD Supra
Recent developments in psychedelic research highlight the potential therapeutic benefits of modified compounds like LSD, ketamine, and psilocybin for mental health issues. New guidelines from Nature Medicine aim to standardize clinical trials, ensuring safety and efficacy. With bipartisan political support and initiatives like Texas's $50 million investment in trials, the regulatory landscape for psychedelic therapies is evolving rapidly.
Nov 21, 2025
DCGI Requires CDSCO Approval for Medical Device Purchases, Reports DrugsControl Media Services
The Drugs Controller General of India (DCGI) has mandated that all medical device procurement must be licensed by the Central Drugs Standard Control Organisation (CDSCO). This initiative aims to enhance regulatory oversight and reduce the entry of substandard medical devices into the market.
Nov 21, 2025
A 133-Year-Old Pharmaceutical Company Reveals Job Cuts and Submits WARN Notice During Reorganization Efforts
Merck & Co. plans to lay off employees as part of a restructuring initiative aimed at saving $3 billion annually by 2027, due to impending patent expirations for Keytruda and Gardasil. The company has filed notices for job cuts, including 204 positions in New Jersey. Despite these layoffs, Merck continues to invest in new drug development, reporting $17.3 billion in Q3 revenue.
Nov 21, 2025
Emphasize quality to ensure that innovation initiatives are effective: DCGI, DrugsControl Media Services
The Drugs Controller General of India, Rajeev Raghuvanshi, emphasized the need for the Indian pharmaceutical industry to prioritize quality to ensure that innovation efforts are not wasted. This call for a cultural shift comes as the regulator aims to align with global standards.
Nov 21, 2025
Exploring Eli Lilly's Groundbreaking Achievement: The Impact of Weight-Loss Medications on the Pharmaceutical Industry
Eli Lilly has made history as the first healthcare company to achieve a trillion-dollar market valuation, driven by soaring demand for its weight-loss drugs, Mounjaro and Zepbound. The company's innovative tirzepatide, a dual-action medication, has significantly impacted obesity treatment, contributing to over $10 billion in revenue. This milestone reflects a transformative moment in the pharmaceutical industry.
Nov 21, 2025
Lilly and Novo Nordisk support direct-to-employer initiatives to increase availability of weight-loss medications.
Eli Lilly plans to launch an employer-focused obesity care model in early 2024, enhancing access to its weight-loss drug through partnerships. The initiative aims to provide flexible cost-sharing and clinical support, addressing coverage gaps. Lilly and Novo Nordisk dominate the obesity treatment market, projected to reach $150 billion by the early 2030s, with their GLP-1 hormone mimicking drugs.
Nov 20, 2025
Daily medication aids individuals in shedding 10% of their body weight over a period of 18 months, according to research.
Eli Lilly has developed a new oral weight loss pill, orforglipron, which offers a needle-free alternative to existing GLP-1 agonists like Mounjaro and Ozempic. In a study, participants lost about 10% of their body weight over 72 weeks. If approved by the FDA, orforglipron could be available by 2026 at a lower cost than current injectables.
Nov 20, 2025
Nuvation Bio Shares Experience Record Surge as Wall Street Becomes Optimistic About Lung Cancer Treatment
Nuvation Bio, Inc. saw its shares surge 49% to $7.15 after Wedbush raised its price target to $11 and B. Riley initiated coverage with a $12 target, citing strong early momentum for its ROS1 lung-cancer therapy. The company reported 204 new patient starts and potential revenues between $220 million and $2 billion. Positive glioma data further fueled investor enthusiasm.
Nov 20, 2025
KIF20A Recognized as a Factor Contributing to Resistance Against Anti-PD-1 Treatment in Non-Small Cell Lung Cancer
Recent research has identified KIF20A as a significant driver of resistance to anti-PD-1 therapy in non-small cell lung cancer (NSCLC). Elevated KIF20A levels in tumors correlate with reduced responsiveness to PD-1 inhibitors, highlighting its role in diminishing the effectiveness of cancer immunotherapy. These findings could inform future strategies to overcome treatment resistance in NSCLC.
Nov 20, 2025
Kerala's Drugs Control Authority confiscates counterfeit Rotacaps valued at ₹2 lakh, according to DrugsControl Media Services.
The Drugs Control department of Kerala has seized counterfeit Rotacaps valued at ₹2 lakh during simultaneous raids in Thiruvananthapuram, Thrissur, and Kozhikode. The operation was conducted by the department's intelligence wing to combat the distribution of spurious medications.
Nov 20, 2025
Can-Fite BioPharma Secures Patent Approval for CF602 as a Treatment for Erectile Dysfunction in ...
Can-Fite BioPharma Ltd. has received a Notice of Allowance for its patent on CF602, a drug candidate for treating erectile dysfunction (ED) in diabetic patients and non-responders to existing medications like Viagra and Cialis. CF602's unique mechanism may address the needs of the 30-35% of ED patients who do not respond to current treatments.
Nov 20, 2025
Can-Fite's CF602 Treatment for Erectile Dysfunction Granted Patent Approval in Brazil
Can-Fite BioPharma Ltd. announced a Notice of Allowance for its patent on CF602, a drug candidate for erectile dysfunction (ED) targeting diabetic patients and non-responders to existing treatments like Viagra and Cialis. CF602's unique mechanism shows promise in improving erectile function, addressing a significant unmet need in the $3.2 billion ED market.
Nov 20, 2025
Can-Fite Secures Brazilian Patent for CF602 Targeting $3.2 Billion Erectile Dysfunction Market | CANF Stock Update
Can-Fite BioPharma Ltd. announced that its erectile dysfunction treatment, CF602, has received a Notice of Patent Allowance in Brazil. This patent expands CF602's intellectual property protection, targeting diabetic patients and those who do not respond to existing medications like Viagra and Cialis. CF602's unique mechanism may address a significant unmet need in the $3.2 billion ED market.
Nov 20, 2025
FDA's strategy to enhance biosimilar medications may face delays at the patent office - Medical Xpress
The FDA plans to streamline the approval process for biosimilars, potentially reducing costs by up to 90% for drugs like Humira and Keytruda. However, the U.S. Patent Office's new rules complicate market entry for these cheaper alternatives, as patent challenges become more difficult. Industry officials express concern over the impact on drug affordability and competition.
Nov 20, 2025
Raids Discover Crores Worth of Illegal Drugs, Increasing Arrests Prompt Demands for Tougher NDPS Regulations
A nationwide crackdown in India has revealed a vast illegal network smuggling Codeine-based cough syrup, leading to drug seizures exceeding ₹45 crore. Authorities have conducted extensive raids, resulting in numerous arrests and heightened calls for stricter enforcement of the Narcotic Drugs and Psychotropic Substances (NDPS) Act.
Nov 20, 2025
Novartis aims for an annual sales increase of 5%-6% through 2030, driven by its important cancer medications - WIBQ
Novartis projects 5% to 6% currency-adjusted sales growth until 2030, driven by increased peak sales forecasts for cancer drugs Kisqali and Scemblix. Kisqali's forecast rises to at least $10 billion, while Scemblix is now expected to reach at least $4 billion. The company also plans to acquire Avidity Biosciences for $12 billion to enhance its portfolio.
Nov 20, 2025
Enforcing Patent Infringement Assumptions on Biosimilars - Mondaq
The article discusses the complexities of patent infringement in the growing biosimilar market in Turkey. It highlights the presumption of patent infringement for biosimilars, similar to generics, and the challenges in proving or defending against such claims. The Turkish Medicines and Medical Devices Agency's guidelines and the potential for intense patent disputes as patents expire are also noted.
Nov 20, 2025
Reducing Prescription Costs Requires Addressing Patent Misuse - Bloomberg Law News
The Department of Health and Human Services is set to release a report on reducing prescription drug prices, focusing on combating patent abuse by pharmaceutical companies. Tactics like "product hopping" and "evergreening" hinder generic competition. The FTC and Justice Department are urged to enforce antitrust laws against these practices to promote affordable medicine for Americans.
Nov 20, 2025
Morgan Stanley Raises Novartis (NVS) Rating to Overweight and Increases Price Target to CHF 110
Novartis AG (NYSE:NVS) has been upgraded by Morgan Stanley to Overweight, with a price target increase to CHF 110. The company reported Q3 2025 revenue of $13.9 billion, an 8% rise, and reaffirmed its 2025 guidance for high single-digit sales growth. Novartis is addressing pipeline challenges as it expands into cancer and autoimmune therapies amid generic competition for key drugs like Entresto.
Nov 20, 2025
Research reveals that a daily medication can assist individuals in shedding 10% of their body weight over a period of 18 months.
Eli Lilly has developed a new oral weight loss pill, orforglipron, which offers a simpler alternative to injectable GLP-1 agonists like Mounjaro. In a study, participants lost about 10% of their body weight over 72 weeks. If approved by the FDA, orforglipron could be available by 2026 at a lower cost than current treatments.
Nov 20, 2025
Novartis experiences an increase in revenue due to important cancer medications - Yahoo Finance
Novartis forecasts annual sales growth of 5% to 6% through 2030, driven by increased peak sales expectations for cancer drugs Kisqali and Scemblix. The company anticipates Kisqali's peak sales to reach at least $10 billion and Scemblix at least $4 billion. Novartis is also focused on acquisitions, including Avidity Biosciences, to enhance its pipeline amid patent expirations.
Nov 20, 2025
A study reveals that Eli Lilly's daily medication aids individuals in shedding 10% of their body weight over a period of 18 months.
A study published on Nov 20 revealed that orforglipron, a needle-free weight loss drug developed by Eli Lilly, helps users lose about 10% of their body weight over 18 months. The drug, part of the GLP-1 agonist class, offers a cheaper alternative to injectable treatments like Mounjaro. If approved, orforglipron could be available in 2026.
Nov 20, 2025
Novo Nordisk Has Boosted Denmark's Economy—But How Long Will It Last? - TradingView
Denmark's GDP surged by 2.3% in Q3, driven primarily by the pharmaceutical sector, particularly Novo Nordisk (NVO). Despite challenges from competition and job cuts, recent data suggests fears about Novo's impact on the economy may be overstated. With rising pharma production and cautious consumer spending, Denmark's growth remains closely tied to Novo's performance amid increasing competition.
Nov 19, 2025
Roche's oral medication demonstrated effectiveness in preventing breast cancer, leading to a rise in stock prices - KFGO
Roche's experimental oral drug giredestrant has demonstrated a significant reduction in breast cancer recurrence risk post-surgery, leading to a 6.1% surge in the company's shares. The late-stage trial results suggest giredestrant may outperform standard endocrine therapy. If approved, it could generate $5 billion annually. Competitors include AstraZeneca's camizestrant, while Sanofi's efforts in this area have faltered.
Nov 19, 2025
Are GLP-1 medications effective in treating Alzheimer's? Novo Nordisk is set to reveal important findings soon.
Novo Nordisk is set to announce results from ambitious studies on its GLP-1 drug semaglutide, marketed as Ozempic and Wegovy, to determine its potential in slowing Alzheimer’s disease progression. Despite the risks, the company is preparing for a possible new indication, recently posting job openings for Alzheimer’s marketing and medical affairs roles.
Nov 19, 2025
Scientists Create Innovative Lyme Disease Test for Quicker and More Accurate Outcomes
Researchers at Dartmouth Hitchcock Medical Center have developed a new molecular test for Lyme disease that can quickly and accurately differentiate between past and current infections. Meanwhile, Novo Nordisk is set to announce results from studies on its GLP-1 drug semaglutide, exploring its potential to slow Alzheimer's progression.
Nov 19, 2025
Merck Invests $9.2 Billion in a Revolutionary Flu Medication
Merck & Co. has announced a $9.2 billion acquisition of Cidara Therapeutics, sending Cidara's stock up over 100%. This strategic move aims to diversify Merck's portfolio ahead of the 2028 patent expiration of its cancer drug, Keytruda. Cidara's investigational flu drug, CD388, is in Phase 3 trials and could generate over $5 billion annually, enhancing Merck's growth prospects.
Nov 19, 2025
Windtree announces further advancements in its istaroxime and next-generation SERCA2a.
Windtree Therapeutics, Inc. announced the allowance of acute heart failure patents in Canada and Mexico, and a new SERCA2a activator patent granted in Israel. The company has a total of 58 patents related to heart failure treatments, including istaroxime, which shows promise in improving cardiac function without increasing arrhythmias. Windtree aims to pursue partnerships for further development.
Nov 19, 2025
Creating Breakthroughs: The Impact of Patent Regulations on Pharmaceutical Innovation | IPWatchdog Unleashed
In a recent IPWatchdog Unleashed podcast, Rob Sahr discussed the critical role of patent law in drug development, emphasizing that strong patent protections are essential for attracting investments in the life sciences sector. He highlighted misconceptions about government funding in drug discovery and expressed optimism for future breakthroughs, contingent on restoring predictability in patent law.
Nov 19, 2025
FDA's Strategy to Enhance Biosimilar Medications May Face Delays at the Patent Office - J&R Report
The FDA announced plans to streamline the approval process for biosimilars, potentially reducing costs by up to 90% for drugs like Humira and Keytruda. However, the U.S. Patent Office's new rules complicate market entry for these cheaper alternatives, hindering competition. Industry officials express concern over the impact of patent challenges on biosimilar availability and pricing.
Nov 19, 2025
Can India's pharmaceutical sector come to the world's rescue once more? - Vox
In 2001, Yusuf Hamied of Cipla revolutionized HIV treatment by offering medications for $1 a day, drastically reducing costs and saving millions of lives. However, India's pharmaceutical industry now faces challenges, including quality control issues and competition from countries like China. As demand for new therapies rises, India's ability to adapt and innovate is crucial for maintaining its role as the "pharmacy of the world.
Nov 19, 2025
The market for generic drugs in the United States is projected to hit USD 231.69 billion.
The U.S. generic drugs market is projected to grow from USD 146.04 billion in 2025 to USD 231.69 billion by 2034, driven by patent expirations, rising chronic diseases, and increased healthcare access. Key players include Teva Pharmaceutical Industries Ltd., Sandoz, and Viatris Inc. The market is supported by government initiatives and technological advancements in drug development.
Nov 19, 2025
Doctor states that new weight-loss medications are effective but necessitate prolonged usage - The Times of India
Recent advancements in weight-loss drugs, particularly GLP-1 receptor analogs like semaglutide (Ozempic, Wegovy) and liraglutide, have shown significant results, with users losing 10-15 kg. However, concerns about side effects and the high cost persist. In India, generic versions are expected post-2026, while new drugs like retatrutide are in development, promising even greater weight loss benefits.
Nov 19, 2025
Nuvation Bio (NUVB) Rises Following the Successful Launch of IBTROZI and Impressive Q3 2025 Results
Nuvation Bio Inc. (NASDAQ: NUVB) saw a 47.71% stock surge after a strong Q3 2025 earnings report, driven by the successful launch of its oncology drug, IBTROZI™ (taletrectinib), for advanced ROS1-positive non-small cell lung cancer. The drug's impressive clinical profile and rapid market uptake position Nuvation Bio as a key player in precision oncology, reshaping the competitive landscape.
Nov 18, 2025
Has the FDA prohibited compounded semaglutide? - Medical News Today
The FDA declared the semaglutide shortage resolved on February 21, 2025, leading to decreased availability of compounded semaglutide. While compounded versions can still be made for specific medical needs, accessing them will be more challenging. Novo Nordisk, the manufacturer of semaglutide products like Ozempic, holds patents that may delay generic availability until 2031 in the U.S.
Nov 18, 2025
Forecast for the Over-the-Counter Medications Market from 2024 to 2031 | Consumer Insights - openPR.com
The global over-the-counter (OTC) drugs market is projected to grow at a CAGR of 5.1% from 2024 to 2031, driven by self-medication trends, rising healthcare costs, and digital pharmacy expansion. Key players like Johnson & Johnson, Bayer AG, and GlaxoSmithKline are innovating with new products and digital health partnerships, enhancing market accessibility and consumer engagement.
Nov 18, 2025
Novo Nordisk Takes a Risky Step: Reducing Prices in the Competition for Weight-Loss Medications - Ad-hoc-news.de
Novo Nordisk is implementing significant price cuts for its weight-loss drugs, Wegovy and Ozempic, in the U.S. to combat competition and declining revenue. This shift from premium pricing to a volume-driven model raises concerns among analysts about future revenue growth. The company is also preparing to launch an oral version of Wegovy, aiming to attract more patients despite reduced profit margins.
Nov 18, 2025
The development of a new medication typically requires over a decade and an investment of 1 trillion won before it can be launched.
Bae Byung-joon, President of Hyundai Bioscience, highlights the challenges in Korea's pharmaceutical R&D, particularly the transition from non-clinical to clinical trials, termed the "Valley of Death." He calls for government support to enhance funding, health insurance coverage, and infrastructure to foster innovation and ensure the development of new drugs, ultimately benefiting public health.
Nov 18, 2025
Roche's oral medication demonstrated effectiveness in preventing breast cancer - Oman Observer
Roche's experimental oral drug giredestrant has demonstrated a significant reduction in breast cancer recurrence risk post-surgery, leading to a 6.1% surge in the company's shares. The late-stage trial results suggest giredestrant may outperform standard endocrine therapy. If approved, it could generate $5 billion annually. Competitors include AstraZeneca's camizestrant, while Sanofi's efforts in this area have faltered.
Nov 18, 2025
The Ongoing Semaglutide Story: Managing Generic Market Entry and Strengthening Patent Protections...
A recent analysis highlights the impending entry of generic semaglutide, the active ingredient in Novo Nordisk's Ozempic® and Wegovy®, into the Canadian market following the lapse of its core patent. Generic manufacturers like Sandoz Canada and Apotex are preparing for launch, potentially reducing costs significantly. This shift could save Canadians over CAD 500 million annually, emphasizing the need for robust patent management strategies.
Nov 18, 2025
Protein Pharmaceuticals Market: Revolutionizing Healthcare through Innovation and Strategic Partnerships
The protein drugs market is rapidly evolving, driven by chronic disease prevalence and biotech advancements. Key players like AbbVie, Amgen, and Roche are expanding portfolios through R&D and strategic partnerships. The rise of biosimilars and innovative therapies, particularly in oncology and autoimmune disorders, is enhancing treatment accessibility. North America leads in innovation, while Asia-Pacific, especially China, is emerging as a significant player.
Nov 18, 2025
Financial institutions and consumer brands strengthen their intellectual property defenses as pharmaceutical companies fall behind.
Recent data from IFI Claims reveals that banks like JPMorgan Chase, Capital One, and Bank of America are leading in patent portfolio growth, focusing on machine learning and payment technologies. In contrast, pharmaceutical companies like Eli Lilly and Amgen show modest growth, while Pfizer and others face declines as patents expire. Johnson & Johnson exemplifies a hybrid strategy with both medtech and pharma patents.
Nov 18, 2025
Trends and Projections for the Generic Pharmaceuticals Market Through 2034 - openPR.com
The Generic Pharmaceuticals Market is projected to grow significantly through 2034, driven by patent expirations, increased FDA approvals, and rising demand for cost-effective alternatives. Key players include Teva Pharmaceutical Industries, Mylan, and Sandoz. The market is expected to reach a multi-hundred-billion-dollar valuation, with a CAGR of 6%-8%, highlighting the growing importance of generics in global healthcare.
Nov 18, 2025
Pfizer Introduces 'Rimegepant ODT' in India: A Breakthrough for Those Dealing with Migraines...
Pfizer has launched Rimegepant ODT in India, a new orally disintegrating tablet aimed at adults with migraines who have limited response to triptans. This innovative treatment is expected to significantly enhance migraine management in the country.
Nov 18, 2025
Establishment of minimum import prices for essential pharmaceutical components, according to DrugsControl Media Services.
The Indian government is nearing the implementation of a minimum import price (MIP) for essential pharmaceutical inputs to protect the domestic industry from aggressive pricing by Chinese raw material suppliers. This move aims to ensure fair competition and stability in the pharmaceutical sector.
Nov 18, 2025
Roche's stock price jumps following a significant advancement in breast cancer treatment - Rolling Out
Roche's shares surged 6.1% to an eight-month high following positive results from its breast cancer drug giredestrant, which significantly reduced disease recurrence risk post-surgery. Analysts project potential revenues of $5 billion if approved. The oral medication, targeting estrogen-responsive tumors, offers a promising alternative to existing treatments, enhancing patient quality of life amid growing competition in the oncology market.
Nov 18, 2025
Merck's potential blockbuster cardiovascular medication achieves positive results in a new heart study - Yahoo Finance
Merck & Co. is advancing its cardiovascular drug Winrevair into late-stage testing for heart failure with preserved ejection fraction (HFpEF) after positive mid-stage trial results. The drug showed significant improvements in blood flow in patients with high blood pressure. This development is critical for Merck as it faces impending patent loss on its top-selling drug, Keytruda.
Nov 18, 2025
Merck's potential blockbuster cardiovascular medication achieves positive results in a new heart study.
Merck & Co. is advancing its cardiovascular drug Winrevair into late-stage testing for heart failure with preserved ejection fraction (HFpEF) after positive mid-stage trial results. The drug showed significant improvements in blood flow in patients with high blood pressure. Winrevair, acquired through Merck's $11.5 billion purchase of Acceleron Pharma, is crucial for the company amid impending patent losses for Keytruda.
Nov 18, 2025
LifeMD announces earnings shortfall and provides disappointing outlook due to intense competition in the GLP-1 sector.
LifeMD's stock fell after reporting a Q3 loss of $0.10 per share, exceeding analyst expectations. The company cited fierce competition from low-cost compounded GLP-1 providers, impacting its weight management segment. LifeMD partners with Novo Nordisk and Eli Lilly, which recently announced price cuts for their GLP-1 drugs, potentially benefiting LifeMD as branded prices align with cheaper alternatives.
Nov 17, 2025
FDA's Strategy to Enhance Biosimilar Medications May Face Delays at the Patent Office - KFF Health News
The FDA announced plans to streamline the approval process for biosimilars, potentially reducing costs by up to 90% for drugs like Humira and Keytruda. However, the U.S. Patent Office's new rules complicate market entry for these cheaper alternatives, hindering competition. Industry officials express concern over the impact of patent challenges on biosimilar availability and pricing.
Nov 17, 2025
Merck USA purchases Cidara Therapeutics for $9.2 billion.
Merck & Co. has announced its acquisition of Cidara Therapeutics for $9.2 billion, aimed at enhancing its antiviral drug portfolio, particularly with the long-acting influenza treatment CD388. This strategic move comes as Merck prepares for patent expirations, including that of Keytruda. The deal is expected to finalize in Q1 2026, pending regulatory approval.
Nov 17, 2025
Upcoming weight loss medications poised to transform the pharmaceutical industry in 2026 - BusinessToday
The weight-loss and diabetes drug market is set for disruption, with new entrants like Eli Lilly's retatrutide and Novo Nordisk's CagriSema expected by 2026. As semaglutide's patents expire, generic options will increase access, particularly in India. Analysts predict a shift in pricing and availability, emphasizing the need for affordability and integration with lifestyle changes.
Nov 17, 2025
Oral Macromolecular Formulation Market Poised for Significant Growth - openPR.com
The oral macromolecular formulation market is projected to grow from $17.2 million in 2022 to $29.5 million by 2033, driven by advancements in drug delivery technologies, particularly for diabetes management, which holds a 45.7% market share. The U.S. leads with 49.6% of the global market, supported by an aging population and innovative research in nanotechnology and oral biologics.
Nov 17, 2025
This Biotech Fund Invests $40 Million in Liquidia Following Major Commercial Success...
TCG Crossover Management has invested approximately $38.9 million in Liquidia Corporation, acquiring 1.7 million shares as the company’s YUTREPIA drug achieved its first full quarter of commercialization. Liquidia reported $51.7 million in Q3 product sales, marking a significant turnaround with positive operating income. The stock has surged 184% over the past year, reflecting strong market performance.
Nov 17, 2025
Novo Nordisk has introduced its anti-obesity medication with prices starting at $199 per month - CryptoRank
Novo Nordisk has announced significant price reductions for its GLP-1 drugs, Wegovy and Ozempic, now available for $199/month for new cash-paying patients for the first two months. This move follows a deal with President Trump to enhance drug accessibility, potentially increasing patient volume but also intensifying pricing pressure. The stock remains cautious, trading over 40% below its yearly high.
Nov 17, 2025
How obesity medications reduce 'food noise' in the brain - Nature
A study published in Nature Medicine reveals that tirzepatide, marketed as Mounjaro or Zepbound, can suppress brain activity linked to food cravings in individuals with obesity. Researchers utilized electrodes to measure brain signals, finding that the drug affects GLP-1 receptors, potentially offering insights into managing compulsive eating behaviors.
Nov 17, 2025
Pharmaceutical company reduces costs for Ozempic and Wegovy. Find out your new price. - USA Today
Novo Nordisk has reduced the prices of its weight loss and diabetes drugs, Wegovy and Ozempic, to $349 a month from $499 for direct purchases. New customers can access introductory prices of $199 for the first two months. This move follows pressure from the Trump administration to lower costs amid rising competition and affordability issues for GLP-1 medications.
Nov 17, 2025
Novo Nordisk reduces monthly prices for Wegovy and Ozempic to $349 for consumers - CNBC
Novo Nordisk has reduced the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment Ozempic, lowering costs for cash-paying patients to $349 per month from $499. A temporary offer allows new patients to access lower doses for $199 for the first two months. This move follows agreements with the Trump administration to enhance accessibility to GLP-1 drugs.
Nov 17, 2025
As patent expiration approaches, Eli Lilly and Novo Nordisk are planning strategies to protect their leading obesity medications in India.
Eli Lilly and Novo Nordisk executives outline their strategies for weight-loss drugs in India, emphasizing pricing, market expansion, and countering generics post-semaglutide patent expiration. Both companies are collaborating with partners to enhance patient access to their innovative therapies, aiming to benefit a broader population across the country.
Nov 17, 2025
Rethinking the Delivery of Advanced Therapies: Understanding the Shortcomings of Promising Medications
Lisa Stehno-Bittel, PhD, founder of Likarda, discusses the challenges of drug delivery for advanced therapies. Likarda's Core-Shell Spherification® technology aims to improve encapsulation and delivery of cell therapies, addressing issues with traditional methods like alginate. Recent studies, including collaboration with Takeda, show promising results for liver disease treatments using their VitaCell™ technology.
Nov 16, 2025
Trial reveals that a single-dose malaria treatment is as effective as a multi-dose approach.
A phase 3 clinical trial in Gabon demonstrated that a single-dose malaria treatment, combining four commonly used malaria drugs, is as effective as traditional multi-dose regimens. This breakthrough could simplify treatment protocols for malaria patients.
Nov 16, 2025
With the rising popularity of GLP-1 medications for obesity, patients are facing high expenses | Mumbai News
The arrival of weight-loss drug Mounjaro (tirzepatide) in India has provided relief for many struggling with obesity, but high costs are causing financial strain. By October, Mounjaro became the highest-selling drug by value, with sales reaching Rs 100 crore. Patients are exploring alternatives as generics remain distant, while some consider bariatric surgery if medications fail.
Nov 16, 2025
Significant study investigates the use of Ozempic for treating alcohol dependence and liver disorders.
A groundbreaking clinical trial sponsored by Novo Nordisk is exploring the use of weight loss medications, including semaglutide (Ozempic), to treat alcohol addiction and alcohol-related liver disease. The study involves 240 patients across multiple countries and aims to assess the drugs' effects on appetite, cravings, and liver inflammation. Early results show promise, with potential transformative impacts on treatment.
Nov 16, 2025
Eli Lilly (LLY): Evaluating Worth Following Government Obesity Agreement and Impressive Earnings Report
Eli Lilly's stock has reached record highs, surpassing $1,025, following a significant deal with the U.S. government to enhance access and reduce costs for its obesity drug, tirzepatide, marketed as Mounjaro. The company's strong third-quarter results and high demand for its weight-loss medications have fueled this surge, raising questions about its valuation and future growth potential.
Nov 16, 2025
Increased Frequency of Low-Grade NMIBC Recurrences Fuels Investigation into Molecular Processes...
Research into low-grade non-muscle invasive bladder cancer (NMIBC) highlights its high recurrence rate, prompting investigations into its molecular mechanisms. Current treatments, including intravesical chemotherapy and immunotherapy, often fall short. Ongoing studies aim to refine these strategies and develop new targeted therapies to better manage this challenging condition.
